Literature DB >> 11494080

A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection.

E Bischoff1, K Schneider.   

Abstract

Experimental models to study the effect of agents on penile erection usually include electrical stimulation of peripheral nerves in anesthetized animals combined with systemic or intracavernous injection of drugs. The objective of this study was to demonstrate that conscious rabbits can be used as a simple and quantitative model for the assessment of compounds that show potential for the treatment of erectile dysfunction. Erection was assessed by measuring the length of uncovered penile mucosa before and after the intravenous (i.v.) administration of agents. Animals did not require anesthesia during the course of the study. The phosphodiesterase 5 (PDE5) inhibitors vardenafil x HCl (hereafter called vardenafil) and sildenafil were given intravenously, and measurements were taken for 0-5 h. The effects of phentolamine and milrinone were also evaluated. Vardenafil (0.1-3 mg/kg) induced dose-dependent penile erections in conscious rabbits following i.v. administration. The efficacy of vardenafil was potentiated, and the minimal effective dose was reduced significantly to 0.01 mg/kg by simultaneous administration of the nitric oxide (NO) donor sodium nitroprusside (SNP). Administration of the NO-synthase inhibitor L-NAME abolished the effect. Sildenafil was effective in this model after i.v. administration. The alpha-adrenergic receptor antagonist phentolamine (0.1, 0.3 and 1 mg/kg i.v.) induced erections with a slower t(max) compared with vardenafil and sildenafil. Intravenous administration of the PDE3 inhibitor milrinone (1 mg/kg i.v.) was less effective than the PDE5 inhibitor vardenafil. The conscious rabbit is a suitable and reliable model for the evaluation of compounds with potential for the treatment of erectile dysfunction. This was demonstrated using compounds that target different signaling pathways that induce smooth muscle relaxation in the penis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494080     DOI: 10.1038/sj.ijir.3900703

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  8 in total

Review 1.  Vardenafil.

Authors:  Douglas Ormrod; Stephanie E Easthope; David P Figgitt
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

Review 3.  Vardenafil: a review of its use in erectile dysfunction.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Spotlight on vardenafil in erectile dysfunction.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 5.  Vardenafil: a new approach to the treatment of erectile dysfunction.

Authors:  Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

6.  Insights into the development and treatment of cardiovascular disease: a role for animal models.

Authors:  Cecil S Thompson
Journal:  Open Cardiovasc Med J       Date:  2010-11-26

Review 7.  Animal models of erectile dysfunction.

Authors:  Snehlata V Gajbhiye; Kshitij S Jadhav; Padmaja A Marathe; Dattatray B Pawar
Journal:  Indian J Urol       Date:  2015 Jan-Mar

8.  Relationship between Response to PDE5 Inhibitors and Penile Duplex Doppler Ultrasound in Erectile Dysfunction.

Authors:  Ercan Ogreden; Ural Oğuz; Erhan Demirelli; Alptekin Tosun; Orhan Yalçın
Journal:  Med Sci (Basel)       Date:  2018-03-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.